Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744287 · ClinicalTrials.gov registry record · Phase 1
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02744287 is a Phase 1 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT02744287, a Phase 1 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA). Participants' T cells are modified to recognize and target the PSCA tumor marker on cancer cells.
Interventions
- DRUG Rimiducid
- BIOLOGICAL BPX-601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2023-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744287
The ClinicalTrials.gov registry entry for NCT02744287 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimiducid is the first listed.
NCT02744287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02744287 about?
NCT02744287 is a clinical study titled "Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors". The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA). Participants' T cells are modified to recognize and target the PSCA tumor mark...
What is the current status of trial NCT02744287?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2016-11-30. Estimated completion is 2023-03-14.
What interventions are being tested in trial NCT02744287?
The interventions under investigation include: Rimiducid (DRUG), BPX-601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02744287?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.